Synonym
YNT 185; YNT185; YNT-185; YNT-185 HCl; YNT-185 hydrochloride;
IUPAC/Chemical Name
3'-[[[3-[[2-[[2-(Dimethylamino)benzoyl]amino]ethyl]amino]phenyl]amino]sulfonyl]-4'-methoxy-N,N-dimethyl-[1,1'-biphenyl]-3-carboxamide dihydrochloride
InChi Key
AIORBDHFHVKRIY-UHFFFAOYSA-N
InChi Code
InChI=1S/C33H37N5O5S.2ClH/c1-37(2)29-15-7-6-14-28(29)32(39)35-19-18-34-26-12-9-13-27(22-26)36-44(41,42)31-21-24(16-17-30(31)43-5)23-10-8-11-25(20-23)33(40)38(3)4;;/h6-17,20-22,34,36H,18-19H2,1-5H3,(H,35,39);2*1H
SMILES Code
O=C(C1=CC(C2=CC=C(OC)C(S(=O)(NC3=CC=CC(NCCNC(C4=CC=CC=C4N(C)C)=O)=C3)=O)=C2)=CC=C1)N(C)C.[H]Cl.[H]Cl
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
688.67
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Takenoshita S, Sakai N, Chiba Y, Matsumura M, Yamaguchi M, Nishino S. An overview of hypocretin based therapy in narcolepsy. Expert Opin Investig Drugs. 2018 Apr;27(4):389-406. doi: 10.1080/13543784.2018.1459561. Epub 2018 Apr 9.Review. PubMed PMID: 29623725.
2: Irukayama-Tomobe Y, Ogawa Y, Tominaga H, Ishikawa Y, Hosokawa N, Ambai S, Kawabe Y, Uchida S, Nakajima R, Saitoh T, Kanda T, Vogt K, Sakurai T, Nagase H, Yanagisawa M. Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models. Proc Natl Acad Sci U S A. 2017 May 30;114(22):5731-5736. doi: 10.1073/pnas.1700499114. Epub 2017 May 15. PubMed PMID: 28507129; PubMed Central PMCID: PMC5465922.
3: Irukayama-Tomobe Y, Yanagisawa M. [Development of a Therapeutic Drug for Narcolepsy]. Brain Nerve. 2018 Nov;70(11):1255-1263. doi: 10.11477/mf.1416201171. Japanese. PubMed PMID: 30416119.
4: Toyama S, Shimoyama N, Tagaito Y, Nagase H, Saitoh T, Yanagisawa M, Shimoyama M. Nonpeptide Orexin-2 Receptor Agonist Attenuates Morphine-induced Sedative Effects in Rats. Anesthesiology. 2018 May;128(5):992-1003. doi: 10.1097/ALN.0000000000002161. PubMed PMID: 29521652.
5: Liu X, Yang R, Bai W, Xu X, Bi F, Zhu M, Dou X, Li H. Exploring the role of orexin B-sirtuin 1-HIF-1α in diabetes-mellitus induced vascular endothelial dysfunction and associated myocardial injury in rats. Life Sci. 2019 Nov 9:117041. doi: 10.1016/j.lfs.2019.117041. [Epub ahead of print] PubMed PMID: 31715188.
6: Yamamoto K, Okui R, Yamatodani A. Activation of orexinergic and histaminergic pathway involved in therapeutic effect of histamine H(4) receptor antagonist against cisplatin-induced anorexia in mice. Naunyn Schmiedebergs Arch Pharmacol. 2019 Aug;392(8):925-936. doi: 10.1007/s00210-019-01646-x. Epub 2019 Mar 27. PubMed PMID: 30919010.
